BioCentury | Sep 6, 2012
Tools & Techniques

Peptide scaffolds for VEGF delivery

...and i.v. infusions of the molecule offered no improvement over placebo. 6 Companies such as Vascular Genetics Inc....
BioCentury | May 5, 2003
Finance

Restructuring watch

...therapy for severe cardiovascular disease. Company is the product of the merger of GenStar and Vascular Genetics...
BioCentury | Feb 10, 2003
Company News

GenStar Therapeutics Corp., Vascular Genetics deal

...now trades on AMEX under the symbol CAQ. GenStar Therapeutics Corp. (GNT), San Diego, Calif. Vascular Genetics Inc....
BioCentury | Nov 25, 2002
Finance

Restructuring watch

...11/14 GenStar (GNT) 30% to about 30 Cuts done in anticipation of its merger with Vascular Genetics...
BioCentury | Nov 25, 2002
Product Development

Telik's sensitive situation

...The company intends to begin pivotal testing using this technique by the end of 2003. Vascular Genetics Inc....
...its naked DNA VEGF-2 gene therapy for cardiovascular disease and angina using a catheter-based procedure. Vascular Genetics...
BioCentury | Nov 18, 2002
Company News

Genstar Therapeutics gene/cell therapy news

...that will be the focus of the company following completion of the planned merger with Vascular Genetics Inc....
BioCentury | Oct 7, 2002
Finance

Pummeling the microcaps

...way back from Monday's news that it wrote down the value of its investment in Vascular Genetics...
BioCentury | Sep 16, 2002
Company News

Genstar Therapeutics, Vascular Genetics deal

...Gene therapy companies Vascular Genetics and GNT will merge in a stock-for-stock deal. The combined company, to...
...combined company, to be called Autus Genetics Corp., will be equally owned by shareholders of Vascular Genetics...
...angina, GNT’s Factor VIII gene therapy, which is in Phase I testing for hemophilia A. Vascular Genetics...
BioCentury | Sep 13, 2002
Company News

Vascular Genetics, GenStar merging

...Gene therapy companies Vascular Genetics (Atlanta, Ga.) and GNT will merge in a stock-for-stock deal. The combined...
...The combined company, to be called Autus Genetics, will be equally owned by shareholders of Vascular Genetics...
...angina, GNT's Factor VIII gene therapy, which is in Phase I testing for hemophilia A. Vascular Genetics...
BioCentury | Nov 19, 2001
Clinical News

VEGF-2: Phase I/II

...ceased experiencing angina altogether. Results were presented at the American Heart Association meeting in Anaheim. Vascular Genetics Inc....
Items per page:
1 - 10 of 33
BioCentury | Sep 6, 2012
Tools & Techniques

Peptide scaffolds for VEGF delivery

...and i.v. infusions of the molecule offered no improvement over placebo. 6 Companies such as Vascular Genetics Inc....
BioCentury | May 5, 2003
Finance

Restructuring watch

...therapy for severe cardiovascular disease. Company is the product of the merger of GenStar and Vascular Genetics...
BioCentury | Feb 10, 2003
Company News

GenStar Therapeutics Corp., Vascular Genetics deal

...now trades on AMEX under the symbol CAQ. GenStar Therapeutics Corp. (GNT), San Diego, Calif. Vascular Genetics Inc....
BioCentury | Nov 25, 2002
Finance

Restructuring watch

...11/14 GenStar (GNT) 30% to about 30 Cuts done in anticipation of its merger with Vascular Genetics...
BioCentury | Nov 25, 2002
Product Development

Telik's sensitive situation

...The company intends to begin pivotal testing using this technique by the end of 2003. Vascular Genetics Inc....
...its naked DNA VEGF-2 gene therapy for cardiovascular disease and angina using a catheter-based procedure. Vascular Genetics...
BioCentury | Nov 18, 2002
Company News

Genstar Therapeutics gene/cell therapy news

...that will be the focus of the company following completion of the planned merger with Vascular Genetics Inc....
BioCentury | Oct 7, 2002
Finance

Pummeling the microcaps

...way back from Monday's news that it wrote down the value of its investment in Vascular Genetics...
BioCentury | Sep 16, 2002
Company News

Genstar Therapeutics, Vascular Genetics deal

...Gene therapy companies Vascular Genetics and GNT will merge in a stock-for-stock deal. The combined company, to...
...combined company, to be called Autus Genetics Corp., will be equally owned by shareholders of Vascular Genetics...
...angina, GNT’s Factor VIII gene therapy, which is in Phase I testing for hemophilia A. Vascular Genetics...
BioCentury | Sep 13, 2002
Company News

Vascular Genetics, GenStar merging

...Gene therapy companies Vascular Genetics (Atlanta, Ga.) and GNT will merge in a stock-for-stock deal. The combined...
...The combined company, to be called Autus Genetics, will be equally owned by shareholders of Vascular Genetics...
...angina, GNT's Factor VIII gene therapy, which is in Phase I testing for hemophilia A. Vascular Genetics...
BioCentury | Nov 19, 2001
Clinical News

VEGF-2: Phase I/II

...ceased experiencing angina altogether. Results were presented at the American Heart Association meeting in Anaheim. Vascular Genetics Inc....
Items per page:
1 - 10 of 33